- Read Article
Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in rheumatoid arthritis are higher than with tumor necrosis factor (TNF) inhibitors.
MMWR recently reviewed the epidemiology and characteristics of U.S. monkeypox cases seen between May and July 2022. They found that 99% of cases occurred in men, 94% of whom reported recent male-to-male sexual or close intimate contact. Current outbreak-associated cases are less likely to have a prodrome and more likely to have genital involvement and racial and ethnic minority groups appear to be disproportionately affected.Read Article
A small retrospective study suggests that patients with difficult to treat adult-onset Still's disease (AOSD) or sytemic juvenile idiopathic arthritis (sJIA) may respond well to JAK inhibitor (JAKi) agents - presumable by blocking pro-inflammatory cytokines, notably IL-6 and IFN.Read Article